Prevention of VTE in Orthopedic Surgery Patients Yngve Falck-Ytter, MD, Charles W. Francis, MD, Norman A. Johanson, MD, Catherine Curley, MD, Ola E. Dahl, MD, Sam Schulman, MD, PhD, Thomas L. Ortel, MD, PhD, Stephen G. Pauker, MD, Clifford W. Colwell, MD  CHEST  Volume 141, Issue 2, Pages e278S-e325S (February 2012) DOI: 10.1378/chest.11-2404 Copyright © 2012 The American College of Chest Physicians Terms and Conditions

Figure 1 [Section 1.3.1] Schematic of estimated incidence rates for LMWH and no prophylaxis for major orthopedic surgery used for this guideline. Additional example data are from observational studies (dashed line), which usually represents a cumulative incidence rate resulting from high rates of prophylaxis in the first 7 to 14 days and low rates or no prophylaxis during the extended prophylaxis period. LMWH = low-molecular-weight heparin. CHEST 2012 141, e278S-e325SDOI: (10.1378/chest.11-2404) Copyright © 2012 The American College of Chest Physicians Terms and Conditions